Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...

Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

Hims & Hers beat first-quarter profit and revenue forecasts as sales more than doubled. However, the health and wellness ...

Hims & Hers Health Inc. posted better-than-expected first-quarter revenue as the company pivots away from making copycat ...

But Hims & Hers' shares fell in after-hours trading as second-quarter projections fell short of analysts' expectations. The ...

Hims & Hers, a digital health platform, saw subscriber growth of 38% to 2.4 million. Monthly online revenue per user also ...

Hims is doubling down on ambitionand it just brought in a heavy hitter to do it. Nader Kabbani, the architect behind Amazon ...

Hims & Hers shares fell in extended trading on Monday after the company reported first-quarter earnings that offered soft ...

There are only a few companies that come around every half-decade or so that really get the gears turning in terms of having ...

Telehealth firm Hims & Hers Health Inc. (HIMS) reported strong first-quarter 2025 results, with revenue more than doubling ...

The new oral drug is viewed as a key product for Novo Nordisk as it tries to case Eli Lilly's Trulicity (dulaglutide), a once-weekly GLP-1 drug that is the market leader in the class with sales of ...